AFP: American Family Physician Podcast

Episode 230 -- May 2025, Part 2
Release Date: June 2, 2025
Hosts: Jake, Valeria, Sati (Residents & faculty, University of Arizona College of Medicine-Phoenix Family Medicine Residency)
Contributing Editor: Dr. Steven Brown

Episode Overview

This episode delivers evidence-based clinical pearls and updates for busy family physicians, centered on key reviews from the May 2025 issue of American Family Physician. Topics covered include migraine prophylaxis, atrial fibrillation management, postmenopausal health maintenance, topical testosterone therapy, pain control in dysmenorrhea, and management of persistent pediatric obstructive sleep apnea. The discussion highlights evolving guidelines, recent studies, and practical takeaways for primary care.

Migraine Headache Prophylaxis

(Starts at 01:35)

Key Discussion Points

• Epidemiology: Migraines impact ~1% of the U.S. population; ~7% meet criteria for chronic migraine. Annually, 2.5% progress from episodic to chronic.
  “Prophylactic treatment isn't just about reducing headache frequency. It also aims to reduce disability, improve response to acute therapies, and give patients more control.” (02:12, Jake)

• Pharmacologic Therapy

  • Beta Blockers (First Line): Propranolol can reduce migraine days by ~1.5/month in 8 weeks.
    “Propranolol is as effective as topiramate and flunarizine for chronic migraine...” (02:41, Sati)
  • Antiepileptics: Topiramate and valproate are also first-line; topiramate roughly doubles the chance of halving migraine days compared to placebo.
    “Valproate's effectiveness is similar...but side effects, especially in women of childbearing age, can limit its use.” (03:09, Valeria)
  • Antidepressants (Second Line): Amitriptyline works but has more side effects. Venlafaxine is better tolerated, but with less robust data.
  • Candesartan: Offers benefit, especially in hypertensive patients.
  • Botox: FDA-approved for chronic migraine; PREEMPT trials showed 50% reduction in headache days after one cycle, up to 74% after 2 years.
    “In the PREEMPT trials, 50% of patients saw a 50% reduction in headache days after just one treatment cycle.” (03:43, Valeria)
  • CGRP Antagonists: Effective and well-tolerated, but insurance issues limit first-line use.

• Non-Pharmacologic Therapy

  • Trigger avoidance (alcohol, caffeine, sleep, stress), hydration, weight management.
  • CBT and relaxation—helpful despite lack of robust RCT data.

• Special Populations

  • Pregnancy: Migraine w/o aura may improve; avoid most prophylactic meds—if needed, propranolol/other beta blockers are preferred.
  • Breastfeeding: Propranolol, amitriptyline, magnesium, Botox are generally safe; no data on CGRP antagonists in lactation.
  • Menstrual Migraine: Triptans/NSAIDs or continuous hormonal contraceptives if no aura.
  • Pediatrics: Limited evidence for meds; prioritize lifestyle modification, mood/anxiety disorder management.

• Summary “Migraine prophylaxis is multifaceted...tailoring therapy to patient specific factors remains essential.” (05:51, Valeria)

Atrial Fibrillation with Stable Coronary Artery Disease

(Starts at 06:11)

Key Study & Insights

• Study Origin: South Korea; >1,000 adults with atrial fibrillation (AFib), stable CAD, and CHA2DS2-VASc ≥2.
• Intervention: Edoxaban (Xa inhibitor) 60mg plus either placebo or antiplatelet.
• Results:
  • Monotherapy group (edoxaban only) had fewer bleeding events and a slightly lower (but nonsignificant) rate of vascular events.
    “The number needed to treat with monotherapy to prevent one major bleeding event...was 10.” (08:11, Sati)
  • Benefit clearer for men than women.
• Practice Takeaway:
  “For patients with afib and stable coronary artery disease, edoxaban monotherapy prevents more adverse bleeding outcomes than edoxaban plus an antiplatelet agent.” (08:26, Jake)
• Level of Evidence: 1B

Health Maintenance in Postmenopausal Women

(Starts at 08:51)

Prevention & Screening

• Average Menopause Age: 52; women spend ~⅓ of life postmenopausal.

• Priorities: Cardiovascular disease (CVD) prevention, cancer screening, osteoporosis, psychosocial well-being, immunizations.

• CVD Screening

  • Screen for diabetes, dyslipidemia (age 40-75), hypertension, obesity, tobacco use. (09:35-10:37)
  • Use ASCVD score for risk stratification.
  • Statin therapy indicated for ASCVD score ≥10%.
    “The USPSTF recommends statins in those with an ASCVD risk score of at least 10% and engage in shared decision making if between 7.5 and 10%.” (10:19, Valeria)

• Non-Cardiac Prevention

  • Breast Cancer: Mammogram q2 years (40-75); consider chemoprevention for high-risk patients.
  • Ovarian Cancer: No routine screening; refer BRCA carriers to genetic counseling.
  • Lung Cancer: Low-dose CT for those 50-80 with ≥20 pack-year history and who are current/former smokers (quit within 15 years).
  • Colorectal Cancer: Screen 45-75 years.
  • Cervical Cancer:
    “Screen patients age 30 through 65 for high risk HPV primary testing or co-testing every five years.” (12:03, Valeria)
    Stop at 65 if history is negative.
  • Osteoporosis: DEXA at ≥65; use FRAX for younger.
  • Other: Counsel on calcium, vitamin D, exercise, and polypharmacy.

• Immunizations: Zoster, COVID-19, Hepatitis B, PCV, RSV, tetanus, influenza.

Topical Testosterone for Sexual Dysfunction in Menopause

(Starts at 13:52)

Evidence Review

• 2017 Meta-Analysis:
  • Transdermal testosterone improved frequency of satisfying sexual episodes vs. placebo. No significant difference between those on systemic hormone therapy plus testosterone vs. testosterone alone.
• 2010 RCT:
  • Combination estrogen + testosterone yielded largest improvement in sexuality scores vs. estrogen alone or control.
• Adverse Effects:
  • More acne, but not more serious androgenic, metabolic, or cancer-related issues long-term. (17:00)
• Long-Term Safety:
  • Over 4 years, serious adverse effects were rare and mild.
• Conclusion:
  “Topical testosterone can be used to manage sexual function and vaginal symptoms associated with menopause.” (17:35, Valeria)
  Especially as adjunct to estrogen therapy.

TENS for Pain Control in Primary Dysmenorrhea

(Starts at 17:57)

Cochrane Review Highlights

• TENS Device: Portable, blocks pain signals through skin electrodes.
• Evidence:
  • Both high and low frequency TENS reduced pain more than placebo/no treatment, with low frequency reducing pain by ~2 points on a 10-point scale.
  • Reduced analgesic use as well.
  • Comparable rates of side effects to control.
• Limitations:
  • Evidence quality: “low to very low” (19:29, Sati)
  • Unclear if TENS is better than NSAIDs or acupressure.
• Practice Takeaway:
  “While promising, TENS isn't ready to replace first line treatments. It could be a nice adjunct...” (19:39, Sati)

Pediatric Obstructive Sleep Apnea (OSA) After Adenotonsillectomy

(Starts at 20:00)

Guideline Review (American Thoracic Society)

• Up to 40% of kids have persistent OSA after surgery, especially those with severe OSA, obesity, craniofacial/genetic disorders.
• Guideline Quality: 8/8 on GTRUST scorecard—clear, actionable, unbiased, and multidisciplinary. (21:23)

Four Main Recommendations:

1. Rapid Maxillary Expansion (if posterior crossbite present) helps resolve OSA for many.
   “Observational studies demonstrate that rapid maxillary expansion reduces average apnea hypopnea index to less than 1 per hour in patients with persistent OSA.” (22:30, Jake)
2. Drug Induced Sleep Endoscopy: Useful to identify lingual tonsil hypertrophy or sleep-dependent laryngomalacia, both surgically correctable.
3. CPAP Therapy: Consider when other treatments not suitable, though adherence can be challenging.
4. Weight Loss Interventions: Recommended for obese children, as obesity is a primary risk factor though evidence for OSA resolution is limited.

Notable Quotes & Memorable Moments

• “Migraine prophylaxis is multifaceted... tailoring therapy to patient specific factors remains essential.” – Valeria (05:51)
• “The number needed to treat with [edoxaban] monotherapy to prevent one major bleeding event was 10.” – Sati (08:11)
• “Topical testosterone can be used to manage sexual function and vaginal symptoms associated with menopause.” – Valeria (17:35)
• “This is low to very low certainty evidence... TENS isn’t ready to replace first-line treatments.” – Sati (19:39)
• “This guideline gets a perfect eight out of eight.” – Jake (21:00)

Timestamps by Topic

• 01:35 – Migraine Prophylaxis
• 06:11 – Atrial Fibrillation + Stable CAD (POEM)
• 08:51 – Health Maintenance in Postmenopausal Women
• 13:52 – Topical Testosterone for Menopausal Symptoms
• 17:57 – TENS for Primary Dysmenorrhea
• 20:00 – Pediatric OSA Management Post-Tonsillectomy (Guideline)

Summary

This episode delivers concise, evidence-based clinical updates with a focus on practical, patient-oriented application. The hosts maintain a friendly, conversational tone, synthesize guidelines and research, and repeatedly underscore the importance of individualizing care to patient context for optimal outcomes.